Benefits of Hydroxychloroquine Combined with Low-Dose Aspirin on Pregnancy Outcomes and Serum Cytokines in Pregnant Women with Systemic Lupus Erythematosus [0.03%]
羟氯喹联合小剂量阿司匹林对系统性红斑狼疮孕妇妊娠结局及血清细胞因子的影响
Na Zhang,Hong-Xia Zhang,Yu-Wei Li et al.
Na Zhang et al.
Background and objective: Systemic lupus erythematosus (SLE) is an autoimmune disease, with hydroxychloroquine being the main therapeutic agent for the treatment of SLE. This research explored the effects of hydroxychloro...
Analyses of Basal and Squamous Cell Carcinoma Reported as an Adverse Drug Reaction and Comparison with Cases from the Cancer Registry from Germany [0.03%]
作为药物不良反应报告的基底细胞和鳞状细胞癌分析以及与德国癌症登记处病例的对比研究
Diana Dubrall,Bernhardt Sachs,Klaus Kraywinkel et al.
Diana Dubrall et al.
Introduction: In Germany, incidence rates of basal cell (BCC) and squamous cell carcinoma (SCC) rose significantly from 1998 to 2010. Ultraviolet (UV) light exposure, immunosuppressants and drugs with photosensitising pot...
Pharmacokinetics, Bioequivalence and Safety of Cloperastine in Chinese Healthy Subjects Under Fasting and Postprandial Conditions [0.03%]
空腹及餐后条件下氯普沙汀在中国健康受试者中的药代动力学、生物等效性及安全性研究
Hong-Yu Luo,Hui-Zhi Long,Zi-Wei Zhou et al.
Hong-Yu Luo et al.
Background: Cloperastine is a pivotal antibechic widely prescribed to treat cough caused by respiratory diseases. The present trial evaluated the pharmacokinetics (PK), bioequivalence (BE) and safety effects of the generi...
Clinical Trial
Drugs in R&D. 2022 Dec;22(4):311-320. DOI:10.1007/s40268-022-00406-2 2022
Chinese- and French-Manufactured Immediate-Release Glucophage® Bioequivalence: A Randomized, Open-Label, Crossover Study [0.03%]
国产和法国生产的格华止(二甲双胍片)生物等效性研究：一项随机开放标记交叉试验
Chaoying Hu,Dan Gao,Dandan Li et al.
Chaoying Hu et al.
Objective: We aimed to assess the bioequivalence, safety, and tolerability of Chinese- and French-manufactured Glucophage® immediate-release (GIR) tablets under fasted and fed conditions in healthy volunteers. A bioequiv...
Randomized Controlled Trial
Drugs in R&D. 2022 Dec;22(4):301-309. DOI:10.1007/s40268-022-00405-3 2022
Clinical Validation of the Covariates Pharmacokinetic Model for Propofol in an Adult Population [0.03%]
用于成人人群的异丙酚协变量药代动力学模型的临床验证
Christopher Hawthorne,Martin Shaw,Ruaraidh Campbell et al.
Christopher Hawthorne et al.
Background and objective: Pharmacokinetic or pharmacokinetic-pharmacodynamic models have been instrumental in facilitating the clinical use of propofol in target-controlled infusion systems in anaesthetic practice. There ...
Randomized Controlled Trial
Drugs in R&D. 2022 Dec;22(4):289-300. DOI:10.1007/s40268-022-00404-4 2022
Quercetin Supplement to Aspirin Attenuates Lipopolysaccharide-Induced Pre-eclampsia-Like Impairments in Rats Through the NLRP3 Inflammasome [0.03%]
檞皮素通过NLRP3炎性小体削弱脂多糖诱导的妊娠高血压综合征小鼠模型中的损伤
Shuangyan Yang,Junfeng Zhang,Dan Chen et al.
Shuangyan Yang et al.
Background and objectives: Aspirin is a common drug for the treatment of pre-eclampsia. We aimed to explore whether quercetin as a supplement to aspirin could enhance the therapeutic outcome in pre-eclampsia rat models. W...
Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation [0.03%]
肾功能对非瓣膜性房颤患者艾多沙班因子Xa活性浓度的影响
Ryohei Ono,Kazutaka Nishimura,Hidehisa Takahashi et al.
Ryohei Ono et al.
Background: Chromogenic anti-factor Xa activity (AXA) assay is used to measure the pharmacodynamics of factor Xa inhibitors, including edoxaban. Although AXA concentrations in patients with non-valvular atrial fibrillatio...
Luay Alkazmi,Hayder M Al-Kuraishy,Gaber El-Saber Batiha et al.
Luay Alkazmi et al.
Matthew W McCarthy
Matthew W McCarthy
On 4 September, 2020, the US National Institutes of Health launched a new clinical trial, "A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized ...
Randomized Controlled Trial
Drugs in R&D. 2022 Dec;22(4):257-262. DOI:10.1007/s40268-022-00400-8 2022
Correction: The Pitfalls of Abnormal Laboratory Value Interpretation in Vaccine Clinical Trials: The Example of Asymptomatic Transient Neutropenia [0.03%]
关于疫苗临床试验中异常实验室检查值解释的误区——无症状短暂性中性粒细胞减少为例
Venanzio Vella,Johannes E Schmidt,Giulia Luna Cilio et al.
Venanzio Vella et al.
Published Erratum
Drugs in R&D. 2022 Sep;22(3):253. DOI:10.1007/s40268-022-00395-2 2022